Compare Wendys Co (WEN) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wendys Co vs GeneDx Holdings Corp — how do they compare? Wendys Co trades at $8.61 (market cap $1.44B), while GeneDx Holdings Corp trades at $82.71 (market cap $2.44B). The key difference: GeneDx Holdings Corp is the larger of the two by market cap, and Wendys Co pays a 3.71% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| WEN | WGS | |
|---|---|---|
Market Cap | $1.44B | $2.44B |
Sector | Consumer Cyclical | Technology |
52-Week High | $10.68 | $167.51 |
52-Week Low | $6.17 | $34.51 |
Enterprise Value | $5.17B | $2.48B |
Dividend Yield | 3.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Wendy's (WEN) stock is trading at $8.57, up 17.4% in 24 hours, with a neutral technical signal and bullish moving averages. The company reported Q2 2026 EPS of $0.18, beating expectations, but faces challenges including a 50% dividend cut, withdrawn 2026 outlook, and declining U.S. same-store sales as Burger King overtakes it as the second-largest U.S. burger chain. Financial metrics show a P/E of 11.44 and ROE of 108.04%, but net income margin has fallen to 5.72% for 2026.
The outlook is cautious; while valuation appears reasonable and recent earnings beats are positive, significant operational headwinds, high debt, and intense competition pose risks. Analyst sentiment is mixed with a majority Hold rating, reflecting uncertainty around the new CEO's turnaround plan. Investment opportunity hinges on successful execution of strategic initiatives to restore growth and profitability.
GeneDx Holdings Corp (WGS) trades at $82.07, up 5.38% in the past 24 hours, with technical indicators showing a bullish trend. The stock beat Q2 2026 EPS estimates but reported negative net income margins. Recent news highlights product expansion and institutional buying interest, though class-action lawsuits pose near-term sentiment risks.
Outlook is mixed: strong analyst buy ratings (90.9%) and a $79.25 consensus target suggest upside, but high valuation multiples and persistent losses require caution. Key risks include profitability challenges and legal overhangs, while revenue growth and market positioning offer long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
